⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTMX News
CytomX Therapeutics, Inc.
CytomX Therapeutics to Present at Upcoming September Investor Conferences
globenewswire.com
CTMX
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
globenewswire.com
CTMX
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
globenewswire.com
CTMX
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
globenewswire.com
CTMX
Form 8-K
sec.gov
CTMX
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
globenewswire.com
CTMX
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
globenewswire.com
CTMX
Form 8-K
sec.gov
CTMX
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
globenewswire.com
CTMX
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
prnewswire.com
GTBP
XNCR
CTMX
ZYME
NRIX